据香港交易所披露，花旗集团对无锡药明康德新药开发股份有限公司 - H股的多头持仓比例于2025年8 月21日从5.12%降至4.11%。 ...

Core Viewpoint - The company, WuXi AppTec, is experiencing a decline in stock price while maintaining a strong position in the CRO and CMO sectors, benefiting from the depreciation of the RMB and showing significant revenue growth in recent reports [1][3][7]. Company Overview - WuXi AppTec is a leading international open-access capability and technology platform providing comprehensive and integrated new drug research and production services for the global biopharmaceutical industry [2]. - The company is a domestic leader in the pharmaceutical outsourcing industry and has been involved in CRO and CMO services since its inception, holding over 200 authorized and pending patents [2]. - The main business focuses on the discovery, research, and production of small molecule chemical drugs, offering a full range of integrated platform services to global pharmaceutical companies [2][7]. Financial Performance - For the first half of 2025, WuXi AppTec achieved revenue of 20.799 billion yuan, representing a year-on-year growth of 20.64%, and a net profit attributable to shareholders of 8.561 billion yuan, which is a 101.92% increase year-on-year [7]. - The company's overseas revenue accounted for 78.67% of total revenue, benefiting from the depreciation of the RMB [3]. Shareholder Information - As of July 15, the number of shareholders in WuXi AppTec was 235,500, with no change in the average circulating shares per person [7]. - The company has distributed a total of 13.027 billion yuan in dividends since its A-share listing, with 9.373 billion yuan distributed over the past three years [8]. Market Activity - On August 27, WuXi AppTec's stock price fell by 1.45%, with a trading volume of 6.037 billion yuan and a turnover rate of 2.50%, resulting in a total market capitalization of 282.705 billion yuan [1]. - The stock has seen a net outflow of 441 million yuan from major funds today, with a continuous reduction in holdings over the past two days [4][5].

Core Insights - The top three companies with the highest AH premium rates are Northeast Electric (00042) at 770.97%, Hongye Futures (03678) at 252.57%, and Andeli Juice (02218) at 238.08% [1][2] - The bottom three companies with the lowest AH premium rates are CATL (03750) at -18.73%, Midea Group (00300) at 6.86%, and Heng Rui Medicine (01276) at 7.43% [1][2] - The companies with the highest deviation values are Beijing Machinery (00187) at 32.43%, Andeli Juice (02218) at 29.55%, and Fudan Zhangjiang (01349) at 29.44% [1][3] - The companies with the lowest deviation values are BYD (01211) at -84.97%, Longpan Technology (02465) at -62.46%, and GAC Group (02238) at -26.17% [1][3] AH Premium Rate Rankings - The top AH stocks by premium rate include: - Northeast Electric (00042): H-share at 0.310 HKD, A-share at 2.25 CNY, premium rate 770.97%, deviation -23.02% [2] - Hongye Futures (03678): H-share at 4.280 HKD, A-share at 12.6 CNY, premium rate 252.57%, deviation 25.11% [2] - Andeli Juice (02218): H-share at 17.780 HKD, A-share at 50.18 CNY, premium rate 238.08%, deviation 29.55% [2] - The bottom AH stocks by premium rate include: - CATL (03750): H-share at 410.200 HKD, A-share at 278.3 CNY, premium rate -18.73%, deviation 1.21% [2] - Midea Group (00300): H-share at 81.500 HKD, A-share at 72.71 CNY, premium rate 6.86%, deviation -1.78% [2] - Heng Rui Medicine (01276): H-share at 72.500 HKD, A-share at 65.03 CNY, premium rate 7.43%, deviation 11.64% [2] Deviation Value Rankings - The top AH stocks by deviation value include: - Beijing Machinery (00187): H-share at 4.950 HKD, A-share at 13.24 CNY, premium rate 220.40%, deviation 32.43% [3] - Andeli Juice (02218): H-share at 17.780 HKD, A-share at 50.18 CNY, premium rate 238.08%, deviation 29.55% [3] - Fudan Zhangjiang (01349): H-share at 3.590 HKD, A-share at 10.06 CNY, premium rate 235.65%, deviation 29.44% [3] - The bottom AH stocks by deviation value include: - BYD (01211): H-share at 115.100 HKD, A-share at 110.68 CNY, premium rate 15.18%, deviation -84.97% [3] - Longpan Technology (02465): H-share at 10.320 HKD, A-share at 14.37 CNY, premium rate 66.76%, deviation -62.46% [3] - GAC Group (02238): H-share at 3.690 HKD, A-share at 7.88 CNY, premium rate 155.83%, deviation -26.17% [3]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

Market Overview - The Shanghai Composite Index fell by 0.39% on August 26, with 17 sectors rising, led by Agriculture, Forestry, Animal Husbandry, and Fishery (up 2.62%) and Beauty and Personal Care (up 2.04%) [1] - The sectors that experienced the largest declines were Pharmaceutical and Biological (down 1.09%) and Non-Bank Financials (down 1.06%) [1] - Overall, there was a net outflow of 68.855 billion yuan in the main funds across the two markets, with only two sectors seeing net inflows: Beauty and Personal Care (net inflow of 276 million yuan) and Agriculture, Forestry, Animal Husbandry, and Fishery (net inflow of 257 million yuan) [1] Pharmaceutical and Biological Sector - The Pharmaceutical and Biological sector saw a decline of 1.09%, with a net outflow of 8.254 billion yuan in main funds [2] - Out of 474 stocks in this sector, 151 stocks rose, 3 stocks hit the daily limit, and 307 stocks fell [2] - The stocks with the highest net inflows included Kangdelai (net inflow of 112 million yuan), Wanbangde (net inflow of 111 million yuan), and Anke Bio (net inflow of 80.217 million yuan) [2] - The stocks with the largest net outflows included Hanyu Pharmaceutical (net outflow of 766 million yuan), WuXi AppTec (net outflow of 706 million yuan), and Sihai Medical (net outflow of 408 million yuan) [2] Fund Flow Analysis Inflow Leaders - Kangdelai: +10.05% with a turnover rate of 10.15% and main fund flow of 111.545 million yuan [3] - Wanbangde: +9.97% with a turnover rate of 8.58% and main fund flow of 110.956 million yuan [3] - Anke Bio: -0.25% with a turnover rate of 9.03% and main fund flow of 80.217 million yuan [3] Outflow Leaders - Hanyu Pharmaceutical: -5.94% with a turnover rate of 16.12% and main fund flow of -766.138 million yuan [4] - WuXi AppTec: -3.18% with a turnover rate of 2.70% and main fund flow of -705.940 million yuan [4] - Sihai Medical: +4.99% with a turnover rate of 37.04% and main fund flow of -407.547 million yuan [4]

药明康德（603259）(02359)公布，2025年8月26日耗资约4280.27万元回购43.98万股A股股份。 ...

据香港交易所披露，花旗集团对无锡药明康德新药开发股份有限公司 - H股的多头持仓比例于2025年8 月20日从4.71%增至5.12%。摩根大通（JPMorgan）对无锡药明康德新药开发股份有限公司 - H股的多头 持仓比例于2025年8月21日从5.87%增至6.01%。 ...

格隆汇8月26日丨药明康德(02359.HK)发布公告，2025年8月26日耗资4280.27万元人民币回购43.98万股 A股，回购价格每股96.68-98.61元。 ...

智通财经APP讯，药明康德(02359)公布，2025年8月26日耗资约4280.27万元回购43.98万股A股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月26日 第 2 頁 共 13 頁 v 1.3.0 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存 ...